预约演示

NextCure jettisons monoclonal antibody to focus on ADC aimed at same target

2023-12-14

交易

临床1期引进/卖出抗体药物偶联物蛋白降解靶向嵌合体

The biotech will shift its resources over to a B7-H4-directed ADC that resulted from a collaboration with LegoChem.

NextCure is dumping a phase 1 monoclonal antiboB7-H4-directed ADC more time on its antibody-drug conjugateLegoChemimed at the same target.

NextCureland-based biotech jumped into the increasingly crowded ADC space in November 2022 when it signed a pact with LegoChem. The idea was to combine the two companies’ resources to find a new use for NextCure’s anti-B7-H4 antibody NC762 as part of an ADC.

Now, NextCure is halting its work on NC762, which had been underADCng a phase 1b trial in solid tumors, citing “the coLegoCheme environment” and “limited activity to date.” Instead, the biotech will shifNextCureresanti-B7-H4 antibodyBNC762directed ADC, dADCed LNCB74, that resulted from the LegoChem collaboration.

“BaseNextCureomprehensive preclinicalNC762 package, we plan to initiate a dose range-findisolid tumorsy study and GMP manufacturing for LNCB74 in early 2024,” the company explained.B7-H4-directed ADC LNCB74

B7-H4 is abnormally expressed by a range of solid tumors and plays a role in key processes such as cell proliferation and metastasis thaLNCB74ort the development and spread of cancers. Because of its limited expression in healthy tissues, multiple companies have identified the cell-surface glycoprotein as a good target for ADCs that deliver cytotoxic payloads to cells with certain markers.

B7-H4H4 targeted ADC was at the center of GSsolid tumorsion upfront licensing deal with Hansoh Pharma in October. The Big Pharma joined the likes of AstraZeneca, which already cancers7-H4-directed ADC called AZD8205 in a phase 2 trial for solid tumors, and Seagen, which has its own candidate in phase 1.

NeB7-H4e has a coADCe of other clinical-stGSK assets in the works. A readout from a phasHansoh Pharma a LAIR-2 fusion protein called NC410 in combinaAstraZenecaeytruda in patients wiB7-H4-directedcADCer is duAZD8205e first half of next yeasolid tumorsame peSeagenthe biotech expects data from a phase 1 dose escalation study of its LAIR-1 monoclonal antibody NC525 in acute myeloid leukemia.